| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Renin, an aspartyl protease that cleaves angiotensinogen to angiotensin I. The peptide contains the renin cleavage site between the Leu and Val residues (Leu-Val). Upon cleavage, the fluorescence quenching is relieved, allowing detection of enzymatic activity.
|
|---|---|
| ln Vitro |
This peptide serves as a direct substrate for renin. In vitro enzyme assays using this FRET substrate demonstrate renin-dependent increase in fluorescence (excitation ~340 nm, emission ~485 nm from edans). It enables continuous monitoring of renin activity in real-time with high sensitivity.
|
| ln Vivo |
The peptide is not used as a therapeutic agent but as a research tool for measuring renin activity in biological samples. It can be used to evaluate renin inhibitor efficacy in plasma or tissue homogenates from animal models or clinical samples.
|
| Enzyme Assay |
Non-cellular enzyme assays: Purified human renin or plasma samples are incubated with the FRET peptide (1-10 uM) in renin assay buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 0.1% BSA) at 37degC. Fluorescence is measured continuously (ex/em: 340/485 nm) over 30-120 minutes. The linear increase in fluorescence indicates renin activity. IC50 values for renin inhibitors are calculated.
|
| Cell Assay |
Not typically used for intact cell experiments as the peptide is not cell-permeable. For cellular renin activity, cell lysates (e.g., from kidney juxtaglomerular cells) are prepared and incubated with the FRET substrate. Alternatively, the peptide can be used in plasma from cell cultures transfected with renin or angiotensinogen.
|
| Animal Protocol |
Not applicable (the peptide is not administered as a drug to animals). However, the substrate can be used to measure ex vivo renin activity in plasma or tissue homogenates collected from animals treated with renin inhibitors or in disease models of hypertension.
|
| ADME/Pharmacokinetics |
No pharmacokinetic data for this FRET peptide as it is an in vitro research tool. In plasma samples, the peptide is stable at 37degC for the duration of typical renin activity assays (up to 2 hours). It should be stored at -20degC in DMSO stock solutions to prevent degradation.
|
| Toxicity/Toxicokinetics |
No toxicity data. This peptide is used exclusively in biochemical assays and is not administered to animals or humans. Standard laboratory safety precautions for handling peptides and DMSO solutions apply.
|
| References | |
| Additional Infomation |
The edans (donor) and dabcyl (acceptor) FRET pair have minimal spectral overlap with autofluorescence of biological samples. The peptide is also known as Renin Substrate I (Fluorogenic). Not for therapeutic use; strictly a research-grade biochemical tool for renin activity measurement and inhibitor screening.
|
| Molecular Formula |
C131H180F3N37O26S
|
|---|---|
| Molecular Weight |
2778.12
|
| Related CAS # |
Arg-Glu(edans)-Ile-His-Pro-Phe-His-Pro-Phe-His-Leu-Val-Ile-His-Thr-Lys(dabcyl)-Arg
|
| Appearance |
Brown to reddish brown solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O :~50 mg/mL (~18.00 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.3600 mL | 1.7998 mL | 3.5996 mL | |
| 5 mM | 0.0720 mL | 0.3600 mL | 0.7199 mL | |
| 10 mM | 0.0360 mL | 0.1800 mL | 0.3600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
